AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK

Inside Information according to Article 17 MAR

AURELIUS Equity Opportunities co-invests in the acquisition of McKesson UK

Grünwald, November 1, 2021 - AURELIUS Elephant Limited, a subsidiary of AURELIUS Equity Opportunities SE & Co. KGaA ("AEO"; ISIN: DE000A0JK2A8) and AURELIUS European Opportunities IV, S.C.A. ("AURELIUS European Opportunities Fund IV"), today signed a binding agreement to acquire the UK business activities of McKesson ("McKesson UK") from McKesson Corporation, Irving, Texas, in a corporate carve-out deal.

The deal with an enterprise value of GBP 477 million will be acquired through the recently launched co-investment structure with AURELIUS European Opportunities Fund IV controlling a 70% stake and AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8) controlling 30%. The transaction is expected to close in Q1 2022, subject to customary closing conditions, including receipt of required regulatory approvals.

The McKesson UK business has an established position in the healthcare sector, comprising Lloyds Pharmacy as well as wholesale pharmaceuticals distributor, AAH Pharmaceuticals and generated over GBP 5 billion in revenues and an EBITDA in the high double-digit millions in 2020.

McKesson UK operates four divisions: retail, digital, homecare and wholesale. The business has over 18,000 employees, including pharmacists, nurses, logistics operatives as well as store, warehouse and administration personnel.

To find out more, visit www.aureliusinvest.com
 

CONTACT
AURELIUS Equity Opportunities SE & Co. KGaA
Investor Relations & Corporate Communications
Phone: +49 (89) 544799 - 0
Fax: +49 (89) 544799 - 55
E-mail: investor@aureliusinvest.de